Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

Key Inclusion Criteria:

- Have a diagnosis of RA (2010 ACR/EULAR criteria) and are ACR functional class I-III.

- Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints (SJC66)) and ≥
6 tender joints (from a tender joint count based on 68 joints (TJC68)) at both
screening and Day 1.

- Limited or no prior treatment with MTX

Key Exclusion Criteria:

- Previous treatment with any janus kinase (JAK) inhibitor

- Previous therapy for longer than 3 months with conventional synthetic disease
modifying antirheumatic drugs (csDMARDs) other than MTX or hydroxychloroquine

- Use of any licensed or investigational biologic disease-modifying antirheumatic drugs
(DMARDs)

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.